Experimental combo targets tough lung cancer
NCT ID NCT07153055
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This early-phase trial is testing whether combining two drugs, lurbinectedin and osimertinib, is safe and effective for people with a rare type of lung cancer called transformed small cell lung cancer. The study plans to enroll 16 adults whose cancer has changed from a common form to this more aggressive type. Researchers will monitor side effects and how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lurbinectedin and osimertinib
What this could lead to
If successful, this could offer a new treatment option for a rare and aggressive lung cancer that has few effective therapies.
What could go wrong
This is a very early, small trial (16 people) testing safety and dosing, so it may not show strong effectiveness or lead to a standard treatment. Side effects from the drug combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.